NCT07303465

To Evaluate the Safety and Efficacy of RNK08954 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma.

A Study to Evaluate the Efficacy and Safety of RNK08954 in Subjects With KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Ranok Therapeutics (Hangzhou) Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a multicenter, open-label, phase Ⅱa study to explore the safety, tolerability, and preliminary efficacy of RNK08954 in metastatic pancreatic ductal adenocarcinoma harboring a KRAS G12D mutation.

Conditions

• KRAS G12D Mutations
• Pancreatic Ductal Adenocarcinoma (PDAC)

Interventions

Type	Name	Description
DRUG	RNK08954	RNK08954 will be administered at the assigned dose level, orally, until disease progression or intolerable toxicity.

Timeline

• Start date: 2025-10-14
• Primary completion: 2026-11-30
• Completion: 2026-11-30
• First posted: 2025-12-24
• Last updated: 2025-12-24

Locations

2 sites across 1 country: China